Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/ki.2015.299 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.
Lancet Diabetes Endocrinol
February 2019
Division of Nephrology, Boston, MA, USA. Electronic address:
Background: Change in albuminuria has strong biological plausibility as a surrogate endpoint for progression of chronic kidney disease, but empirical evidence to support its validity is lacking. We aimed to determine the association between treatment effects on early changes in albuminuria and treatment effects on clinical endpoints and surrograte endpoints, to inform the use of albuminuria as a surrogate endpoint in future randomised controlled trials.
Methods: In this meta-analysis, we searched PubMed for publications in English from Jan 1, 1946, to Dec 15, 2016, using search terms including "chronic kidney disease", "chronic renal insufficiency", "albuminuria", "proteinuria", and "randomized controlled trial"; key inclusion criteria were quantifiable measurements of albuminuria or proteinuria at baseline and within 12 months of follow-up and information on the incidence of end-stage kidney disease.
Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis.
Am J Kidney Dis
July 2014
Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT.
Background: It is controversial whether proteinuria is a valid surrogate end point for randomized trials in chronic kidney disease.
Study Design: Meta-analysis of individual patient-level data.
Setting & Population: Individual patient data for 9,008 patients from 32 randomized trials evaluating 5 intervention types.
Renal biopsy findings among Indigenous Australians: a nationwide review.
Kidney Int
December 2012
Centre for Chronic Disease, School of Medicine, The University of Queensland, Herston, Queensland, Australia.
Australia's Indigenous people have high rates of chronic kidney disease and kidney failure. To define renal disease among these people, we reviewed 643 renal biopsies on Indigenous people across Australia, and compared them with 249 biopsies of non-Indigenous patients. The intent was to reach a consensus on pathological findings and terminology, quantify glomerular size, and establish and compare regional biopsy profiles.
View Article and Find Full Text PDFCKD in Aboriginal Australians.
Am J Kidney Dis
November 2010
Centre for Chronic Disease, The University of Queensland, Brisbane, Queensland, Australia.
Chronic kidney disease (CKD) is one component of a spectrum of chronic disease in Aboriginal Australians. CKD is marked by albuminuria, which predicts renal failure and nonrenal natural death. Rates vary greatly by community and region and are much higher in remote areas.
View Article and Find Full Text PDFEffect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease.
Scand J Urol Nephrol
February 2010
Renal Medicine, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Objective: Autosomal dominant polycystic kidney disease (ADPKD) is progressive, resulting in end-stage kidney failure in most patients. Experimental and clinical studies have suggested that statins may slow the progression of chronic kidney disease in general and ADPKD specifically.
Material And Methods: This randomized open-label clinical trial was conducted to assess the effect of pravastatin 20 mg on kidney function and urinary protein excretion in patients with ADPKD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!